References:
- HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.
- van der Heijde D, Kivitz A, Schiff MH, et al; for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136-2146.
- van der Heijde D, Salonen D, Weissman BN, et al; for the Canadian (M03-606) study group and the ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127.
- van der Heijde DM, Revicki DA, Gooch KL, et al; for the ATLAS Study Group. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 2009;11(4):R124.
- Davis JC Jr, Revicki D, van der Heijde DMF, et al. Health‐related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007;57(6):1050-1057.
- Data on file, AbbVie Inc. ABVRRTI69264.
- Data on file, AbbVie Inc. ABVRRTI70163.
- Data on file, AbbVie Inc. ABVRRTI70582.
- Data on file, AbbVie Inc. ABVRRTI69846.
- Data on file, AbbVie Inc. ABVRRTI62920.